國家衛生研究院 NHRI:Item 3990099045/9220

NHRI > Institute of Biotechnology and Pharmaceutical Research > Ching-Chuan Kuo > Conference Papers/Meeting Abstract > Item 3990099045/9220

Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/9220

Title:	High expression of Hsp90-beta and GRP 94 association with poor survival in resected non-small cell lung cancer patients
Other Titles:	High expression of Hsp90-β and GRP 94 association with poor survival in resected non-small cell lung cancer patients
Authors:	Chen, SH;Kuo, CC;Li, CF;Tsou, TC;Chiang, HC;Chang, KY;Cheung, CHA;Chan, LT;Chang, JY
Contributors:	Institute of Biotechnology and Pharmaceutical Research;National Institute of Environmental Health Sciences;National Institute of Cancer Research
Abstract:	Background: Heat Shock Protein 90 (Hsp90) is an ATP-dependent molecular chaperone that was required for the stability and function of more than 200 signaling proteins that promote cancer cell growth and/or survival. It exists as multiple isoforms that includes Hsp90-alpha and Hsp90-beta in the cytoplasm and GRP94 and TRAP1 localized to the ER and mitochondria, respectively. We investigated the relationship with clinical outcome and the expression of Hsp90-beta, GRP94 in the resected non-small cell lung cancer (NSCLC) patient. Methods: We obtained surgical tissue specimens from 208 patients with NSCLC (stage IA, 40; stage IB, 57; stage IIA, 22; stage IIB, 50; stage IIIA, 27; stage IIIB, 12) who underwent surgical resection of their tumors for immunohistochemical analyses of Hsp90-beta, GRP94. Clinical characteristics, survival were analyzed according to immunohistochemical expression of Hsp90-beta, GRP94 using the χ2 test, Kaplan–Meier method, and Cox proportional hazard model. Results: No correlations were observed between the expression of Hsp90-beta, GRP94 and several clincopathological factors. In a survival analysis, the expression of Hsp90-beta was significantly related to overall survival (OS, log-rank test, p=0.021). The OS was 95.97 months (95% confidence interval[CI], 48.31~143.63) with the low expression group of Hsp90-beta, as compared with 31.6 months (95% CI, 10.58~52.62) with high expression group (hazard ratio[HR], 1.95; 95% CI, 1.08~3.48). The expression of GRP94 was also significantly related to OS(log-rank test, p=0.036). The OS was 72.43 months (95% CI, 47.58~97.29) with the low expression group of GRP94, as compared with 32.27 months (95% CI, 18.48~46.06) with high expression group (HR, 1.64; 95% CI, 1.03~2.63). Conclusions: We found that the immunohistochemically high expression of Hsp90-beta, GRP94 were independent prognostic factors for reduced survival, although further large prospective studies are needed to validate our findings.
Date:	2014-05
Relation:	Journal of Clinical Oncology. 2014 May;32(15, Suppl.):e13522.
Link to:	http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/e13522
JIF/Ranking 2023:	http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0732-183X&DestApp=IC2JCR
Cited Times(WOS):	https://www.webofscience.com/wos/woscc/full-record/WOS:000358613200222
Appears in Collections:	[Ching-Chuan Kuo] Conference Papers/Meeting Abstract [Tsui-Chun Tsou] Conference Papers/Meeting Abstract [Kwang-Yu Chang] Conference Papers/Meeting Abstract [Li-Tzong Chen] Conference Papers/Meeting Abstract [Jang-Yang Chang] Conference Papers/Meeting Abstract

Files in This Item:

File	Description	Size	Format
ISI000358613200222.pdf		53Kb	Adobe PDF	546	View/Open

Loading...